NPPA Fixes Retail Price Of 12 Formulations, Details
New Delhi: Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA), the Ministry of Chemicals and Fertilizers, Government of India has fixed the retail price of 12 formulations including Non-steroidal anti-inflammatory drugs (NSAIDs), antidiabetic drugs, antihypertensive drugs and others.
This came in line with the decision of the 107th authority meeting dated 11.01.2023, where the Authority discussed new drug applications for price fixation, under the Drug ( Price Control) Order 2013.
These include Akum Pharmaceuticals/Apex Laboratories Glimepiride, Voglibose & Metformin (Extended- release) tablets, Alicons Pharmaceuticals/ Dale Laboratories Paracetamol, Phenylephrine Hydrochloride, Diphenhydramine Hydrochloride and Caffeine Tablets, Akums Pharmaceutical's/Torrent Pharma's Paracetamol, Phenylephrine and Chlorpheniramine Tablets, Pure & Cure Pharmaceuticals/ Intas Pharmaceuticals Desvenlafaxine Extended Release and Clonazepam Tablets, Ravenbhel Healthcare/Intas Pharmaceuticals Thiocolchicoside, Aceclofenac and Paracetamol Tablet, Ravenbhel Healthcare/Abbott Healthcare Telmisartan, Chlorthalidone & Metoprolol (ER) Tablets, Pure & Cure/ Zydus Pharma's Montelukast and Acebrophylline (SR) Tablets, Pure & Cure/ Torrent Pharma's Pantoprazole Tablets and others.
In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May 2013 and S. O. 5249(E) dated 11th November 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
1. | Glimepiride, Voglibose & Metformin (Extended- release) tablets | Each uncoated bilayered tablet contains: Glimepiride IP 2mg, Voglibose IP 0.2mg Metformin Hydrochloride IP 500mg (as Extended- release) | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Apex Laboratories Pvt. Ltd. | 13.83 |
2. | Paracetamol, Phenylephrine Hydrochloride, Diphenhydrami ne Hydrochloride and Caffeine Tablets | Each uncoated tablet contains: Paracetamol IP 500mg Phenylephrine Hydrochloride IP 5mg Diphenhydramine Hydrochloride IP 25mg Caffeine (Anhydrous) IP 30mg | 1 Tablet | M/s Alicon Pharmaceuticals Pvt. Ltd. / M/s Dales Laboratories Pvt. Ltd. | 2.76 |
3. | Paracetamol, Phenylephrine and Chlorphenirami ne Tablets | Each film coated tablet contains: Paracetamol IP 500mg Phenylephrine Hydrochloride IP 10mg Chlorpheniramine maleate IP 2mg | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Torrent Pharmaceuticals Limited | 4.36 |
4. | Desvenlafaxine Extended Release and | Each uncoated bilayered tablet contains: | 1 Tablet | M/s Pure & Cure Healthcare Pvt. Ltd. / M/s Intas | 13.24 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
Clonazepam Tablets | Desvenlafaxine Succinate USP eq. to Desvenlafaxine 50mg (As extended-release form) Clonazepam IP 0.25mg | Pharmaceuticals Ltd. | |||
5. | Thiocolchicosid e, Aceclofenac and Paracetamol Tablet | Each film coated tablet contains: Thiocolchicoside IP 8mg Aceclofenac IP 100 mg Paracetamol IP 325 mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Intas Pharmaceuticals Ltd. | 24.78 |
6. | Telmisartan, Chlorthalidone & Metoprolol (ER) Tablets | Each film coated bilayered tablet contains: Telmisartan IP 40mg Chlorthalidone IP 12.5mg Metoprolol Succinate IP 23.75mg eq. to Metoprolol Tartrate (as Extended release) 25mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Abbott Healthcare Pvt. Ltd. | 10.90 |
7. | Telmisartan, Chlorthalidone & Metoprolol (ER) Tablets | Each film coated bilayered tablet contains: Telmisartan IP 40mg Chlorthalidone IP 12.5mg Metoprolol Succinate IP 47.50mg eq. to Metoprolol Tartrate (as Extended release) 50mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Abbott Healthcare Pvt. Ltd. | 13.15 |
8. | Rosuvastatin & Clopidogrel Capsules | Each Hard gelatin capsule cotains: Rosuvastatin Calcium IP eq. to Rosuvastatin 10mg Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg | 1 Capsul e | M/s Windlas Biotech Limited. / M/s Modi- Mundipharma Pvt. Ltd. | 13.66 |
9. | Rosuvastatin & Clopidogrel Capsules | Each Hard gelatin capsule cotains: Rosuvastatin Calcium IP eq. to Rosuvastatin 20mg Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg | 1 Capsul e | M/s Windlas Biotech Limited. / M/s Modi- Mundipharma Pvt. Ltd. | 16.96 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
10. | Rosuvastatin, Clopidogrel & Aspirin Capsule | Each Hard gelatin capsule cotains: Rosuvastatin Calcium IP eq. to Rosuvastatin 20mg Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg Aspirin IP 75mg | 1 Capsul e | M/s Windlas Biotech Limited. / M/s Modi- Mundipharma Pvt. Ltd. | 20.53 |
11. | Montelukast and Acebrophylline (SR) Tablets | Each uncoated bilayered tablet contains: Montelukast Sodium IP eq. to Montelukast 10mg Acebrophylline 200mg (As Sustained release) | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Zydus Healthcare Limited | 16.12 |
12. | Pantoprazole Tablets IP | Each enteric coated tablet contains: Pantoprazole Sodium IP eq. to Pantoprazole 20mg | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Torrent Pharmaceuticals Limited | 6.68 |
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd